62 related articles for article (PubMed ID: 2499164)
21. The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime.
Steiniche T; Hasling C; Charles P; Eriksen EF; Melsen F; Mosekilde L
Bone; 1991; 12(3):155-63. PubMed ID: 1910957
[TBL] [Abstract][Full Text] [Related]
22. Etidronate disodium in postmenopausal osteoporosis.
Heaney RP; Saville PD
Clin Pharmacol Ther; 1976 Nov; 20(5):593-604. PubMed ID: 824086
[TBL] [Abstract][Full Text] [Related]
23. The use of cyclical etidronate in osteoporosis: changes after completion of 3 years treatment.
Fairney A; Kyd P; Thomas E; Wilson J
Br J Rheumatol; 1998 Jan; 37(1):51-6. PubMed ID: 9487251
[TBL] [Abstract][Full Text] [Related]
24. [Effects of activate-depress-free-repeat (ADFR) treatment on bone mass in old beagles with osteoporosis].
Kuranobu K
Nihon Seikeigeka Gakkai Zasshi; 1990 May; 64(5):430-41. PubMed ID: 2380595
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms underlying the effects of phosphate and calcitonin on bone histology in postmenopausal osteoporosis.
Marie PJ; Caulin F
Bone; 1986; 7(1):17-22. PubMed ID: 3964494
[TBL] [Abstract][Full Text] [Related]
26. Preliminary observations of a form of coherence therapy for osteoporosis.
Anderson C; Cape RD; Crilly RG; Hodsman AB; Wolfe BM
Calcif Tissue Int; 1984 May; 36(3):341-3. PubMed ID: 6432299
[TBL] [Abstract][Full Text] [Related]
27. The time of day that etidronate is ingested does not influence its therapeutic effect in osteoporosis.
Cook GJ; Blake GM; Fogelman I
Scand J Rheumatol; 2000; 29(1):62-4. PubMed ID: 10722260
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of low turnover osteoporosis resulting from prolonged reserpine therapy with intermittent calcitonin and phosphate therapy.
Armamento-Villareal RC; Avioli LV
Calcif Tissue Int; 1992 Oct; 51(4):282-4. PubMed ID: 1422973
[TBL] [Abstract][Full Text] [Related]
29. Retention of etidronate in human, dog, and rat.
Kasting GB; Francis MD
J Bone Miner Res; 1992 May; 7(5):513-22. PubMed ID: 1615760
[TBL] [Abstract][Full Text] [Related]
30. [Comparative study of dimephosphon and xidiphone efficacy in steroid-induced osteoporosis in rats].
Ziganshina LE; Burnasheva ZA; Valeeva IKh; Galiautdinova AIu; Samoĭlova NS
Eksp Klin Farmakol; 2000; 63(6):39-42. PubMed ID: 11202511
[TBL] [Abstract][Full Text] [Related]
31. Morphological analysis of iliac crest bone biopsies in patients with osteoporosis and treatment according to the ADFR concept with (1-38)hPTH and diphosphonate (EHDP)--Osteoporosis Study I, Hannover.
Delling G; Dreyer T; Vogel M; Hahn M; Rittinghaus EF; Hesch RD
Klin Wochenschr; 1989 May; 67(10):556. PubMed ID: 2500559
[No Abstract] [Full Text] [Related]
32. Treatment with etidronate for men with idiopathic osteoporosis.
Geusens P; Vanhoof J; Raus J; Dequeker J; Nijs J; Joly J
Ann Rheum Dis; 1997 Apr; 56(4):280. PubMed ID: 9166007
[No Abstract] [Full Text] [Related]
33. Effect of sodium etidronate in adult cats.
Jowsey J; Holley KE; Linman JW
J Lab Clin Med; 1970 Jul; 76(1):126-33. PubMed ID: 5450261
[No Abstract] [Full Text] [Related]
34. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; 2008(1):CD003376. PubMed ID: 18254018
[TBL] [Abstract][Full Text] [Related]
35. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials.
Cardona JM; Pastor E
Osteoporos Int; 1997; 7(3):165-74. PubMed ID: 9205627
[TBL] [Abstract][Full Text] [Related]
36. The role of bisphosphonates in the prevention and treatment of osteoporosis.
Reginster JY
Clin Rheumatol; 1995 Sep; 14 Suppl 3():22-5. PubMed ID: 8846657
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonates in osteoporosis?
Bijvoet OL; Valkema R; Löwik CW; Papapoulos SE
Osteoporos Int; 1993; 3 Suppl 1():230-6. PubMed ID: 8461570
[No Abstract] [Full Text] [Related]
38. Bisphosphonates and osteoporosis.
Sørensen OH; Storm T; Thamsborg G; Sørensen HA; Kollerup G; Steiniche T; Melsen F; Genant HK
Osteoporos Int; 1993; 3 Suppl 1():223-5. PubMed ID: 8461567
[No Abstract] [Full Text] [Related]
39. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.
Hasling C; Charles P; Jensen FT; Mosekilde L
Osteoporos Int; 1994 Jul; 4(4):191-203. PubMed ID: 7949749
[TBL] [Abstract][Full Text] [Related]
40. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Dunn CJ; Fitton A; Sorkin EM
Drugs Aging; 1994 Dec; 5(6):446-74. PubMed ID: 7858370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
